title: [Efficiency of hepatitis C virus screening before and after blood transfusion].
abstract: Efficiency of a viral hepatitis C screening strategy before and after blood transfusion has to be evaluated.
  
  
  METHODS
  Four screening strategies were virtually applied to the population of transfused patients at Rouen University Hospital during 1996 and then compared : the first without any systematic HCV screening test; the second with systematic testing both before and 3 months after transfusion; the third with systematic testing both before and 6 months after transfusion ; the last defined as systematic testing before transfusion only. The efficacy (i.e. number of positive tests), the efficiency (i.e. average cost per positive test) and the marginal costs of moving from a strategy to another one were assessed using decision analysis.
  
  
  RESULTS
  The efficacy of systematic screening test before transfusion only (361 per positive test), systematic testing both before and three months after (523 per positive test) or six months after (488 per positive test) transfusion was similar, but the efficacy of the strategy without any systematic screening test (385 per positive test) was lower. The systematization of screening test both before, and three months, or 6 months after transfusion lead to a marginal cost of 619 , and 559 per positive test respectively. The systematization of testing before transfusion only lead to a marginal cost of 343 per positive test. Adding systematic testing after transfusion lead to a marginal cost of 5824 per positive test.
  
  
  CONCLUSIONS
  Systematic screening tests before transfusion only can be considered as the most efficient strategy.
authors.affiliation: Département d'épidémiologie et de santé publique, Unité d'information médicale, CHU de Rouen, 1, rue de Germont, 76031 Rouen, France. valerie.josset@chu-rouen.fr
authors.forename: V
authors.initials: V
authors.lastname: Josset
authors.forename: P
authors.initials: P
authors.lastname: Chamouni
authors.forename: M P
authors.initials: MP
authors.lastname: Tavolacci
authors.forename: V
authors.initials: V
authors.lastname: Merle
authors.forename: V
authors.initials: V
authors.lastname: Delbos
authors.forename: L
authors.initials: L
authors.lastname: Froment
authors.forename: J
authors.initials: J
authors.lastname: Ladner
authors.forename: N
authors.initials: N
authors.lastname: Ounnoughene
authors.forename: P
authors.initials: P
authors.lastname: Czernichow
mesh_terms: D001803:Blood Transfusion / Q000592:standards*; D005500:Follow-Up Studies; D005602:France; D016174:Hepacivirus / Q000302:isolation & purification*; D006526:Hepatitis C / Q000517:prevention & control* / Q000635:transmission; D008403:Mass Screening; D065227:Transfusion Reaction